Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: Comparison of two clinical experiences

被引:68
作者
Ripamonti, C
De Conno, F
Groff, L
Belzile, M
Pereira, J
Hanson, J
Bruera, E
机构
[1] Natl Canc Inst, Pain Therapy & Palliat Care Div, I-20133 Milan, Italy
[2] Univ Alberta, Cross Canc Inst, Dept Med, Div Palliat Care Med, Edmonton, AB, Canada
[3] Univ Alberta, Grey Nuns Community Hlth Ctr, Palliat Care Program, Edmonton, AB, Canada
关键词
cancer; equianalgesia; hydromorphone; methadone; pain;
D O I
10.1023/A:1008263910494
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Oral methadone is considered to be a valid opioid analgesic alternative to morphine and hydromorphone in treating cancer pain. However, the use of methadone could be complicated by the limited knowledge of the equianalgesic dose/ratio with the other analgesic opioids when switching in tolerant patients. Patients and methods. In two Palliative Care Units, data collected regarding 88 advanced cancer patients with pain switched from different opioids to oral methadone were reviewed and compared with the aim of determining the equianalgesic dose ratio in relation to the dose of opioid previously administered. Results: The results of this retrospective study suggest that: (1) methadone is much more potent than previously described in literature, (2) the dose ratio between hydromorphone and methadone is higher than as suggested by equianalgesic tables, and (3) the ratio correlates with total opioid dose administered before switching. Conclusions: The fact that methadone ratio is different according to the opioid dose used previously should be taken into careful consideration by the clinician in order to avoid severe toxicity or death during switchover. Prospective studies should be carried out in order to better define our findings.
引用
收藏
页码:79 / 83
页数:5
相关论文
共 29 条
[1]   CUSTOM-MADE CAPSULES AND SUPPOSITORIES OF METHADONE FOR PATIENTS ON HIGH-DOSE OPIOIDS FOR CANCER PAIN [J].
BRUERA, E ;
WATANABE, S ;
FAINSINGER, RL ;
SPACHYNSKI, K ;
SUAREZALMAZOR, M ;
INTURRISI, C .
PAIN, 1995, 62 (02) :141-146
[2]  
Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO
[3]  
2-T
[4]   CHANGING PATTERN OF AGITATED IMPAIRED MENTAL STATUS IN PATIENTS WITH ADVANCED CANCER - ASSOCIATION WITH COGNITIVE MONITORING, HYDRATION, AND OPIOID ROTATION [J].
BRUERA, E ;
FRANCO, JJ ;
MALTONI, M ;
WATANABE, S ;
SUAREZALMAZOR, M .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1995, 10 (04) :287-291
[5]  
Bruera E, 1990, J Pain Symptom Manage, V5, P1, DOI 10.1016/S0885-3924(05)80002-8
[6]  
CHERNY NJ, 1995, CANCER-AM CANCER SOC, V76, P1283, DOI 10.1002/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO
[7]  
2-0
[8]   IS DISEASE PROGRESSION THE MAJOR FACTOR IN MORPHINE-TOLERANCE IN CANCER PAIN TREATMENT [J].
COLLIN, E ;
POULAIN, P ;
GAUVAINPIQUARD, A ;
PETIT, G ;
PICHARDLEANDRI, E .
PAIN, 1993, 55 (03) :319-326
[9]  
COYLE N, 1989, CANCER, V63, P2289, DOI 10.1002/1097-0142(19890601)63:11<2289::AID-CNCR2820631138>3.0.CO
[10]  
2-M